Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) Revenue (2021 - 2025)

Inmune Bio's Revenue history spans 5 years, with the latest figure at $50000.0 for Q1 2025.

  • For Q1 2025, Revenue rose 257.14% year-over-year to $50000.0; the TTM value through Sep 2025 reached $50000.0, up 19.05%, while the annual FY2024 figure was $14000.0, 90.97% down from the prior year.
  • Revenue for Q1 2025 was $50000.0 at Inmune Bio, up from $14000.0 in the prior quarter.
  • Across five years, Revenue topped out at $163000.0 in Q4 2021 and bottomed at $4000.0 in Q1 2021.
  • The 5-year median for Revenue is $43000.0 (2023), against an average of $59538.5.
  • The largest annual shift saw Revenue soared 3975.0% in 2022 before it plummeted 76.69% in 2023.
  • A 5-year view of Revenue shows it stood at $163000.0 in 2021, then plummeted by 40.49% to $97000.0 in 2022, then tumbled by 71.13% to $28000.0 in 2023, then crashed by 50.0% to $14000.0 in 2024, then surged by 257.14% to $50000.0 in 2025.
  • Per Business Quant, the three most recent readings for INMB's Revenue are $50000.0 (Q1 2025), $14000.0 (Q1 2024), and $28000.0 (Q4 2023).